Rakovina Therapeutics (TSXV:RKV) LT-Debt-to-Total-Asset : 0.26 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Rakovina Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Rakovina Therapeutics's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.26.

Rakovina Therapeutics's long-term debt to total assets ratio increased from Sep. 2023 (0.23) to Sep. 2024 (0.26). It may suggest that Rakovina Therapeutics is progressively becoming more dependent on debt to grow their business.

Rakovina Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Rakovina Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics LT-Debt-to-Total-Asset Chart

Rakovina Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

0.26

Rakovina Therapeutics Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial										0.23	0.26	0.29	0.22	0.26

Rakovina Therapeutics LT-Debt-to-Total-Asset Calculation

Rakovina Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1.333	/	5.148
	=

Rakovina Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	1.396	/	5.308
	=

Rakovina Therapeutics (TSXV:RKV) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Rakovina Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Rakovina Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (TSXV:RKV) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

RKVTF:USA 7JO:Germany

Address

595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC, CAN, V6B 0A5

Website

https://www.rakovinatherapeutics.com

Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some of its products in the pipeline include kt-2000 AI, kt-3000 series. Rakovina gained exclusive use of the Deep Docking AI Platform, enabling it to significantly speed up identifying potential drugs for DNA damage response.

Executives

Alfredo De Lucrezia	Director, Senior Officer
Michael Liggett	Director
Jeffrey Bacha	Senior Officer
Mads Daugaard	Senior Officer
David Hyman	Senior Officer
John Michael Langlands	Senior Officer

Rakovina Therapeutics Headlines

No Headlines